|本期目录/Table of Contents|

[1]邵金曼,唐晓凤,刘妍,等.替诺福韦酯对阿德福韦酯应答不佳患者的挽救治疗研究进展[J].传染病信息,2017,06:371-375.
 SHAO Jin-man,TANG Xiao-feng,LIU Yan*,et al.Progress in rescue therapy of tenofovir disoproxil fumarate forchronic hepatitis B patients with suboptimal virologic response to adefovir dipivoxil[J].Infectious Disease Information,2017,06:371-375.
点击复制

替诺福韦酯对阿德福韦酯应答不佳患者的挽救治疗研究进展(PDF)

《传染病信息》[ISSN:1007-8134/CN:11-3886/R]

期数:
2017年06期
页码:
371-375
栏目:
综述
出版日期:
2017-12-20

文章信息/Info

Title:
Progress in rescue therapy of tenofovir disoproxil fumarate forchronic hepatitis B patients with suboptimal virologic response to adefovir dipivoxil
作者:
邵金曼唐晓凤刘妍徐东平
100039,北京大学三〇二临床医学院(邵金曼、徐东平);100039 北京,解放军第三〇二医院全军传染病研究所/ 临床研究管理中心(刘妍、徐东平);250022,山东省济南市72790 部队卫生所(唐晓凤)
Author(s):
SHAO Jin-man TANG Xiao-feng LIU Yan* XU Dong-ping*
Peking University 302 Clinical Medical College, 100039, China
关键词:
乙型肝炎替诺福韦酯阿德福韦酯耐药抗病毒治疗
Keywords:
hepatitis B tenofovir disoproxil fumarate adefovir dipivoxil drug resistance antiviral therapy
分类号:
R512.6
DOI:
10.3969/j.issn.1007-8134.2017.06.015
文献标识码:
A
摘要:
阿德福韦酯(adefovir dipivoxil, ADV)作为常用抗HBV 治疗药物,与拉米夫定(lamivudine, LAM)、替比夫定和恩替卡韦无交叉耐药,且价格相对低廉,长期以来用于初治患者和LAM 耐药患者的挽救治疗。然而由于ADV 耐药基因屏障较低且临床用药剂量较低,临床长期应用累积了较多ADV 应答不佳患者。替诺福韦酯 (tenofovir disoproxil fumarate,TDF)作为ADV 应答不佳患者的挽救治疗方案之一,对ADV 初治应答不佳患者和LAM 耐药的ADV 应答不佳患者的临床疗效略有差异。然而多项体外研究显示TDF 对ADV 耐药病毒株抑制作用减弱。ADV 应答不佳的患者换用TDF 是否会引起或加重肾损害值得临床关注。本文就TDF 对ADV 应答不佳患者挽救治疗的国内外研究进展作综述,为提高耐药HBV 感染防治的管理提供帮助。
Abstract:
As the common anti-HBV drug, adefovir dipivoxil (ADV) has been recommended for the rescue therapy oflamivudine-resistant and treat-na?ve patients due to its less cost and no cross-resistance to lamivudine, telbivudine and entecavir.However, since ADV has a lower resistance gene barrier and lower clinical dose, patients with suboptimal virologic response to ADVaccumulated during long-term antiviral treatment in clinic. Tenofovir disoproxil fumarate (TDF) has been recommended for the rescuetherapy of the patients with suboptimal virologic response to ADV. TDF shows unequal efficacy in lamivudine-experienced and ADVna?vepatients. And some studies in vitro reported that ADV resistance mutations reduce susceptibility to TDF. Whether TDF treatmentcan increase or aggravate the risk of nephrotoxicity for ADV-experienced patients should be concerned in clinical practice. This reviewaims to summarize progresses in rescue therapy of TDF for chronic HBV-infected patients with suboptimal virologic response to ADV,which will provide help for management of drug-resistant HBV infection

参考文献/References

[1] Lim YS. Management of antiviral resistance in chronic hepatitis B [J]. Gut Liver, 2017, 11(2):189-195.
[2] 中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南[J]. 传染病信息,2005,18(Suppl):1-12.
[3] Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy andsafety of adefovir dipivoxil for the treatment of hepatitis B eantigen-positive chronic hepatitis B[J]. Hepatology, 2008,48(3):750-758.
[4] Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Longtermtherapy with adefovir dipivoxil for HBeAg-negative chronichepatitis B for up to 5 years[J]. Gastroenterology, 2006,131(6):1743-1751.
[5] 周怡,刘妍,徐东平,等. 多重耐药HBV 感染特点及挽救治疗策略[J]. 传染病信息,2017,30(2):109-114.
[6] 中华医学会肝病学分会,中华医学会感染病学分会. 《慢性乙型肝炎防治指南》(2015 更新版) [J]. 传染病信息,2015,28(6):321-340.
[7] Liu Y, Miller MD, Kitrinos KM. HBV clinical isolates expressingadefovir resistance mutations show similar tenofovir susceptibilitiesacross genotypes B, C and D[J]. Liver Int, 2014, 34(7):1025-1032.
[8] Murakami E, Tsuge M, Hiraga N, et al. Effect of tenofovir disoproxilfumarate on drug-resistant HBV clones[J]. J Infection, 2016,72(1):91-102.
[9] Liu Y, Corsa AC, Buti M, et al. No detectable resistance to tenofovirdisoproxil fumarate in HBeAg+ and HBeAg- patients with chronichepatitis B after 8 years of treatment[J]. J Viral Hepat, 2017,24(1):68-74.
[10] Lampertico P, Agarwal K, Berg T, et al. EASL 2017 clinicalpractice guidelines on the management of hepatitis B virus infection [J]. J Hepatol, 2017, 67(2):370-398.
[11] Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for thetreatment of hepatitis B e antigen-positive chronic hepatitis B[J].N Engl J Med, 2003, 348(9):808-816.
[12] Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovirdipivoxil for the treatment of hepatitis B e antigen-negative chronichepatitis B[J]. N Engl J Med, 2003, 348(9):800-807.
[13] Carrouee-Durantel S, Durantel D, Werle-Lapostolle B, et al.Suboptimal response to adefovir dipivoxil therapy for chronichepatitis B in nucleoside-naive patients is not due to pre-existingdrug-resistant mutants[J]. Antivir Ther, 2008, 13(3):381-388.
[14] Tan J, Degertekin B, Wong SN, et al. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure toadefovir in the absence of adefovir-resistant mutations[J]. JHepatol, 2008, 48(3):391-398.
[15] Berg T, Moller B, Trinh H, et al. Tenofovir disoproxil fumarate (TDF)versus emtricitabine plus TDF (FTC/TDF) for treatment of chronichepatitis B (CHB) in patients with persistent viral replicationreceiving adefovir dipivoxil[J]. J Hepatol, 2009, 50:S328-S328.
[16] Chung GE, Cho EJ, Lee JH, et al. Tenofovir has inferior efficacyin adefovir-experienced chronic hepatitis B patients comparedto nucleos(t)ide-naive patients[J]. Clin Mol Hepatol, 2017,23(1):66-73.
[17] Lo AO, Wong GL. Current developments in nucleoside/nucleotideanalogues for hepatitis B[J]. Expert Rev Gastroenterol Hepatol,2014, 8(6):607-622.
[18] Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil addedto ongoing lamivudine in chronic hepatitis B with YMDD mutanthepatitis B virus[J]. Gastroenterology, 2004, 126(1):81-90.
[19] Sinn DH, Lee HI, Gwak GY, et al. Virological response to adefovirmonotherapy and the risk of adefovir resistance[J]. World JGastroenterol, 2011, 17(30):3526-3530.
[20] Lee YS, Suh DJ, Lim YS, et al. Increased risk of adefovir resistancein patients with lamivudine-resistant chronic hepatitis B after 48weeks of adefovir dipivoxil monotherapy[J]. Hepatology, 2006,43(6):1385-1391.
[21] van B?mmel F, Z?llner B, Sarrazin C, et al. Tenofovir for patientswith lamivudine-resistant hepatitis B virus (HBV) infection andhigh HBV DNA level during adefovir therapy[J]. Hepatology,2006, 44(2):318-325.
[22] van Bommel F, de Man RA, Wedemeyer H, et al. Long-termefficacy of tenofovir monotherapy for hepatitis B virus-monoinfectedpatients after failure of nucleoside/nucleotide analogues[J].Hepatology, 2010, 51(1):73-80.
[23] Kumada H, Koike K, Suyama K, et al. Efficacy and safety oftenofovir disoproxil fumarate rescue therapy for chronic hepatitis Bpatients who failed other nucleos(t)ide analogs[J]. Hepatol Res,2017, 47(10):1032-1041.
[24] van B?mmel F, Trojan J, Deterding K, et al. Evolution of adefovirresistantHBV polymerase gene variants after switching to tenofovirdisoproxil fumarate monotherapy[J]. Antivir Ther, 2012,17(6):1049-1058.
[25] Lee YB, Lee JH, Lee DH, et al. Efficacy of entecavir-tenofovircombination therapy for chronic hepatitis B patients withmultidrug-resistant strains[J]. Antimicrob Agents Chemother,2014, 58(11):6710-6716.
[26] Lo AO, Wong VW, Wong GL, et al. Efficacy of tenofovir switchtherapy for nucleos(t)ide-experienced patients with chronichepatitis B[J]. Aliment Pharmacol Ther, 2015, 41(11):1190-1199.
[27] Suzuki F, Suzuki Y, Hosaka T, et al. Efficacy of long-termtenofovir-based rescue therapy in patients with chronic hepatitis Brefractory to nucleoside/nucleotide analogs[J]. J Gastroenterol,2017, 52(5):641-651.
[28] Lim YS, Lee YS, Gwak GY, et al. Monotherapy with tenofovirdisoproxil fumarate for multiple drug-resistant chronic hepatitis B:3-year trial[J]. Hepatology, 2017, 66(3):772-783.
[29] Zhou Y, Liu Y, Chen Y, et al. Extending duration is essential fortenofovir-based antiviral for the patients with history of multidrugresistant HBV infection[J]. Hepatol Int, 2017, 11 (Suppl 1):S701.
[30] Segovia MC, Chacra W, Gordon SC. Adefovir dipivoxil inchronic hepatitis B: history and current uses[J]. Expert OpinPharmacother, 2012, 13(2):245-254.
[31] 孙予州. 阿德福韦酯的不良反应分析[J]. 中国现代药物应用,2014,8(24):10-12.
[32] Tanji N, Tanji K, Kambham N, et al. Adefovir nephrotoxicity:Possible role of mitochondrial DNA depletion[J]. Hum Pathol,2001, 32(7):734-740.
[33] Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxilfumarate versus adefovir dipivoxil for chronic hepatitis B[J]. NEngl J Med, 2008, 359(23):2442-2455.
[34] Fontana RJ. Side effects of long-term oral antiviral therapy forhepatitis B[J]. Hepatology, 2009, 49(Suppl 5):S185-S195.
[35] Perazella MA. Tenofovir-induced kidney disease: an acquired renaltubular mitochondriopathy[J]. Kidney Int, 2010, 78(11):1060-1063.
[36] Kohler JJ, Hosseini SH, Green E, et al. Tenofovir renal proximaltubular toxicity is regulated by OAT1 and MRP4 transporters[J].Lab Invest, 2011, 91(6):852-858.
[37] Kohler JJ, Hosseini SH, Hoying-Brandt A, et al. Tenofovir renaltoxicity targets mitochondria of renal proximal tubules[J]. LabInvest, 2009, 89(5):513-519.
[38] Manns M, Heathcote J, Marcellin P, et al. Efficacy of tenofovirdf treatment in patients with a suboptimal response to adefovirdipivoxil[J]. J Hepatol, 2010, 52:S393-S393.
[39] Hou J, Gao Z, Xie Q, et al. 144 weeks tenofovir disoproxil fumaratemonotherapy or switching from adefovir dipivoxil after 48 weeksresults in potent viral suppression and a favorable safety profile inChinese patients with chronic hepatitis B[J]. Hepatol Int, 2015,9:S30-S31.
[40] Lampertico P, Mangia G, Viganò M, et al. Tenofovir monotherapyis effective for adefovir experienced patients but requires carefulmonitoring of glomerular and tubular function and proactive dosereductions: a 4-year study in 320 patients[J]. Hepatology, 2013,58(4):649A-650A.

备注/Memo

备注/Memo:
[基金项目] 国家自然科学基金面上项目(81371852,81573676)
[通信作者] 徐东平,E-mail: xudongping302@sina.com; 刘妍,E-mail: liuyan5360@163.com
更新日期/Last Update: 2017-12-20